valsartan has been researched along with guanosine monophosphate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aronovitz, MJ; Blanton, RM; Jaffe, IZ; Martin, GL; Pande, S; Richards, DA; Tam, K | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
2 other study(ies) available for valsartan and guanosine monophosphate
| Article | Year |
|---|---|
Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cyclic GMP-Dependent Protein Kinase Type I; Drug Combinations; Guanosine Monophosphate; Heart Failure; Male; Mice; Mice, Inbred C57BL; Random Allocation; Valsartan; Ventricular Function, Left | 2020 |
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Guanosine Monophosphate; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Troponin T; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2022 |